BeyondSpring (NASDAQ:BYSI – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.49, FiscalAI reports.
BeyondSpring Trading Up 9.4%
Shares of NASDAQ:BYSI traded up $0.13 during trading on Wednesday, hitting $1.52. 32,868 shares of the stock were exchanged, compared to its average volume of 23,423. The company has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $1.71. The company has a market cap of $62.50 million, a PE ratio of -10.13 and a beta of 0.41. BeyondSpring has a 12-month low of $1.21 and a 12-month high of $3.44.
Hedge Funds Weigh In On BeyondSpring
A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp purchased a new position in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
View Our Latest Stock Report on BYSI
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
Featured Stories
- Five stocks we like better than BeyondSpring
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
